Published on : Dec 11, 2018
Albany, New York, December 11, 2018: A long standing disorder detrimental to the brain hampering people regardless of their ages, epilepsy, has engulfed more than 50 million of people, concludes World Health Organization (WHO). Epilepsy has an indelible impact as stigma, discrimination, apprehension and misunderstanding hover around the quality of life for people with the disorder. Basically, the prognosis attributed with epilepsy has pushed the demand for enhanced therapeutics. These insights are according to the report titled, “Epilepsy Therapeutics in Asia-Pacific Markets to 2024-Uptake of Novel Therapies and Rising Awareness is Expected to Drive the Market Growth,” which has been recently added in the archive of Market Research Hub (MRH). The assessment of the report infers that epilepsy therapeutics in Asia-Pacific markets is projected to attain $1.7 billion in 2024 at the CAGR of 3.5%.
Though around 80% of the people inflicted with epilepsy live in low and middle income countries, the epilepsy therapeutics market has been bolstered by enhanced economy and rise in disposable income. Furthermore, the pipeline products aimed at unmet or untouched needs for the disorder have propelled the market. In order to provide sophisticated treatment, government has started the initiatives to increase awareness and provide access to healthcare. However, to reiterate, social stigma attached with epilepsy has dented the market. In addition, low availability of anti-epileptic drugs (AEDs) and treatment gap are major roadblocks in the development of epilepsy therapeutics in Asia-Pacific. Moreover, feeble patent protection rights and impending patent cliffs have marred the market.
Epilepsy Therapeutics in Asia-Pacific Market: Report Content
The report provides a thorough analysis on epilepsy therapeutics in Asia-Pacific market. Further, report peruses the drivers of epilepsy therapeutics in the market along with restraints challenging the market. Besides, the report assesses opportunities and trends in the market.
The report incorporates the analysis on pipeline, thereby providing assessment on the molecular target, fitepla, cenobamate(YKP3089), comparative efficacy and product competitiveness. The report also includes analysis of clinical trial which covers failure rate, patient enrollment and clinical trial duration.
The report starts with the introduction of the disease along with assimilations on epidemiology, etiology and pathophysiology. The report also delves into the prognosis and treatment options providing an in-depth view of the market.
Epilepsy Therapeutics in Asia-Pacific Market: Research Methodology
A robust research methodology has been adopted with regards to providing a research approach incorporating of secondary and primary research. The insights in the report is the result of an in-depth secondary research, primary interviews and in-house reviews by panel of experts.
The secondary research embodies company websites, annual reports, and statistical data from trade associations, government and agencies. The primary research embodies face to face interviews, phonic interviews and e-mail interaction. To furnish the readers with an unbiased report, a panel of expert analyzes the data collected from various sources.
Request a Sample with TOC in a PDF format : https://www.marketresearchhub.com/enquiry.php?type=S&repid=1944805
Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.
MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients
For Enquiries, Call :
+1-800-998-4852US Toll Free
Email : firstname.lastname@example.org